{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:39:25Z","timestamp":1790969965862,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2527,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1093\/annonc\/mds282","type":"journal-article","created":{"date-parts":[[2012,9,22]],"date-time":"2012-09-22T00:34:41Z","timestamp":1348274081000},"page":"145-152","source":"Crossref","is-referenced-by-count":59,"title":["A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"S.B.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Da\u0144ska-Bidzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Del Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gorbunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Novikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.A.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds282_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds282_bb0015","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds282_bb0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds282_bb0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","article-title":"Overview of epithelial cancer management. Part II Treatment of recurrent disease","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds282_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543781003647966","article-title":"Current treatment and clinical trials in ovarian cancer","volume":"19","author":"Han","year":"2010","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1093\/annonc\/mds282_bb0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1996.53","article-title":"The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer","volume":"73","author":"Bartlett","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds282_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/hyb.1998.17.313","article-title":"Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues","volume":"17","author":"Bast","year":"1998","journal-title":"Hybridoma"},{"key":"10.1093\/annonc\/mds282_bb0045","first-page":"4087","article-title":"Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer","volume":"50","author":"Berchuck","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds282_bb0050","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/(SICI)1097-4644(19990615)73:4<522::AID-JCB10>3.0.CO;2-4","article-title":"Characteristics of EGFR family-mediated HRG signals in human ovarian cancer","volume":"73","author":"Campiglio","year":"1999","journal-title":"J Cell Biochem"},{"key":"10.1093\/annonc\/mds282_bb0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mds282_bb0060","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2005.04.8397","article-title":"ErbB-3 predicts survival in ovarian cancer","volume":"24","author":"Tanner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds282_bb0065","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mds282_bb0070","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mds282_bb0075","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0002-9378(91)90508-O","article-title":"Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor","volume":"164","author":"Rodriguez","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1093\/annonc\/mds282_bb0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mds282_bb0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1196\/annals.1430.003","article-title":"Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis","volume":"1130","author":"Diermeier-Daucher","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mds282_bb0090","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/cncr.21533","article-title":"2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth","volume":"104","author":"Takai","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds282_bb0095","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","article-title":"Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status","volume":"24","author":"Gordon","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds282_bb0100","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","article-title":"Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer","volume":"28","author":"Makhija","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds282_bb0105","first-page":"4575","article-title":"A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines","volume":"51","author":"Hancock","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds282_bb0110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"24 Suppl","key":"10.1093\/annonc\/mds282_bb0115","article-title":"Pooled analysis of cardiac safety in patients treated with pertuzumab","volume":"69","author":"Suter","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds282_bb0120","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds282_bb0125","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mds282_bb0130","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/1535-7163.MCT-05-0192","article-title":"Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment","volume":"4","author":"Westfall","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mds282_bb0135","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds282_bb0140","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1093\/annonc\/mds282_bb0145","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/jco.2008.26.15_suppl.5520","article-title":"A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer","volume":"26","author":"Kaye","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/1\/145\/13789326\/mds282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:23:48Z","timestamp":1624519428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419370516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0923753419370516"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds282","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}